Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan vs Lansoprazole PK/PD in Healthy Subjects
NCT04729101Phase 1Completed
- Sponsor
- Phathom Pharmaceuticals
- Start
- Jan 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vonoprazan in gastroesophageal reflux disease (GERD) and Helicobacter pylori infection (2 arms), sponsored by Phathom Pharmaceuticals. Primary endpoints: Gastric pH >4 Holding Time Ratio at Day 7, Mean Gastric pH Over a 24-hour Monitoring Period at Day 7 and 7 more. Started Jan 2021; status: completed.
02
Drugs
vonoprazan
03
Conditions
gastroesophageal reflux disease (GERD)Helicobacter pylori infection
Beyond the preview
Go deeper on NCT04729101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04729101.